Breast Cancer | Specialty

Role for Neratinib Following Adjuvant Dual-Targeted HER2 Therapy

February 2nd 2018

Diarrhea Prophylaxis With Neratinib

February 2nd 2018

Optimal Timing for Neratinib

February 2nd 2018

Which Chemotherapy With Adjuvant Trastuzumab and Pertuzumab?

February 2nd 2018

Factors Influencing Adjuvant Therapy Use for HER2+ Breast Cancer

February 2nd 2018

The ExteNET Trial

February 2nd 2018

The APHINITY Trial

February 2nd 2018

Adjuvant Therapy for Early-Stage HER2+ Breast Cancer

February 2nd 2018

Tucatinib Combo Explored in HER2-Positive Breast Cancer

February 1st 2018

Rashmi K. Murthy, MD, MBE, discusses the role of tucatinib in CNS metastases for patients with HER2-positive breast cancer.

Dr. Francis Discusses the SOFT Trial for Breast Cancer

February 1st 2018

Prudence Francis, MD, Peter MacCallum Cancer Centre, discusses the SOFT trial for patients with breast cancer.

Developing Treatment for Invasive Lobular Carcinoma

January 31st 2018

Steffi Oesterreich, PhD, professor and vice chair of Precision and Translational Pharmacology, University of Pittsburgh, discusses developing treatment for patients with invasive lobular carcinoma (ILC).

Dr. Bardia on Sacituzumab Govitecan in Triple-Negative Breast Cancer

January 31st 2018

Aditya Bardia, MD, MPH, assistant professor of medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses a trial investigating sacituzumab govitecan for patients with triple-negative breast cancer (TNBC).

Enzalutamide Shows Early Promise in AR-Positive TNBC

January 30th 2018

Enzalutamide showed promising clinical activity in patients with androgen receptor–positive triple-negative breast cancer.

Dr. Carey Discusses the CALGB40502 Trial in TNBC

January 30th 2018

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses the CALGB 40502/NCCTG N063H trial in patients with triple-negative breast cancer (TNBC).

Dr. King on Role of Sentinel Lymph Node Biopsy in Breast Cancer

January 30th 2018

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses the role of sentinel lymph node biopsy in breast cancer.

Dr. Goetz on the MONARCH Trials for Breast Cancer

January 30th 2018

Matthew P. Goetz, MD, professor of oncology and pharmacology, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the MONARCH trials for patients with breast cancer.

Combos May Extend Reach of CDK4/6 Inhibitors in Breast Cancer

January 29th 2018

Oncology drug developers have been able to leverage knowledge about a cause of proliferation— dysregulated activity of the cyclin-dependent kinases (CDKs)—to create a new class of therapy that has rapidly been integrated into the breast cancer treatment paradigm.

Dr. Ellis on Immunotherapy in HER2+ Breast Cancer

January 23rd 2018

Matthew J. Ellis, MD, PhD, professor of oncology and medicine at Baylor College of Medicine, discusses developments with immunotherapy for patients with HER2-positive breast cancer.

Study Finds No Cardiac Toxicity Increase With Trastuzumab in HER2+ Breast Cancer Patients

January 17th 2018

Trastuzumab did not reduce cardiac function in women with node-positive, HER2+, early-stage breast cancer.

Progress for TNBC Seen Across Treatment Modalities

January 15th 2018

Although chemotherapy remains the mainstay of treatment for patients with triple-negative breast cancer, promising developments are unfolding on several fronts, including new ways of using existing therapies and the exploration of immunotherapy, novel antibodies, and agents targeting the PI3K/mTOR/AKT pathway.